• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Preclinical Data on ARIAD's Molecularly Targeted Oncology Programs to Be Presented at the American Association for Cancer Research Meeting

Posted on: Tuesday, 28 March 2006, 09:01 CST

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that investigators from leading academic cancer-research centers and ARIAD will present data from six collaborative studies focused on compounds from ARIAD's oncogenic kinase inhibitor and bone-targeted mTOR inhibitor programs at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C., April 1 to April 5, 2006.

"These preclinical studies illustrate the progress that has been made in ARIAD's preclinical drug-discovery programs over the past year and the potential for these molecularly targeted compounds to expand our oncology pipeline," said Timothy P. Clackson, Ph.D., chief scientific officer of ARIAD.

The schedule and meeting places for the oral and poster sessions, together with the abstract and poster numbers, are listed below: Sunday, April 2, 2006 from 1:00 p.m. to 5:00 p.m. Abstract No. 962; Poster Presentation (Board No. 14) "Src as a novel therapeutic target in ovarian carcinoma" Presenter: Liz Y. Han, M.D., MD Anderson Cancer Center, Houston, Texas Location: Exhibit Hall, Poster Section 23 Sunday, April 2, 2006 from 1:00 p.m. to 5:00 p.m. Abstract No. 1116; Poster Presentation (Board No. 11) "Bone-targeted rapamycin analogs inhibit osteolysis and tumor growth in a PC-3-GFP intratibial bone cancer model in nude mice" Presenter: Chester A. Metcalf III, Ph.D., ARIAD Pharmaceuticals, Inc. Location: Exhibit Hall, Poster Section 28 Monday, April 3, 2006 from 10:10 a.m. to 10:25 a.m. Abstract No. 2294; Oral Presentation "Lyn activation is necessary for Ewing's sarcoma tumor growth in a mouse model" Presenter: Hui Guan, M.D., Ph.D., MD Anderson Cancer Center, Houston, Texas Location: Room 151 Tuesday, April 4, 2006 from 2:25 p.m. to 2:40 p.m. Abstract No. 4852; Oral Presentation "Targeted inhibition of gatekeeper variant 'T315I' of BCR-ABL by a purine-based ATP competitive inhibitor" Presenter: Mohammad Azam, Ph.D., Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts Location: Room 151 Tuesday, April 4, 2006 from 3:25 p.m. to 3:40 p.m. Abstract No. 4867; Oral Presentation "Chemosensitization by dual pharmacological inhibition of MEK and mTOR signaling pathways in human non-small cell lung cancer (NSCLC)" Presenter: Marie E. Legrier, Ph.D., Albert Einstein College of Medicine, Bronx, New York Location: Room 144 Tuesday, April 4, 2006 from 3:40 p.m. to 3:55 p.m. Abstract No. 4857; Oral Presentation "A tissue selective rapamycin analog inhibits MDA-MB-231 breast cancer cell-induced osteolytic bone metastases in nude mice" Presenter: Chester A. Metcalf, III, Ph.D., ARIAD Pharmaceuticals, Inc. Location: Room 151

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat disease by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. Medinol Ltd. also is developing stents and other medical devices that deliver ARIAD's lead cancer product candidate to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.

Some of the matters discussed herein are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are identified by the use of words such as "anticipate,""estimate,""expect,""project,""intend,""plan,""believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding our ability to accurately estimate the timing and actual R&D expenses and other costs associated with the preclinical and clinical development and manufacture of our product candidates, the adequacy of our capital resources and the availability of additional funding, risks and uncertainties regarding our ability to manufacture or have manufactured our product candidates on a commercial scale, risks and uncertainties regarding our ability to successfully enroll and conduct clinical studies of product candidates, risks and uncertainties that clinical trial results at any phase of development may be adverse or may not be predictive of future results or lead to regulatory approval of any of our or any partner's product candidates, risks and uncertainties of third-party intellectual property claims relating to our and any partner's product candidates, and risks and uncertainties relating to regulatory oversight, the timing, scope, cost and outcome of legal proceedings, including litigation concerning our NF-(kappa)B patent portfolio, future capital needs, key employees, dependence on collaborators and manufacturers, markets, economic conditions, products, services, prices, reimbursement rates, competition and other factors detailed in the Company's public filings with the Securities and Exchange Commission, including ARIAD's Annual Report on Form 10-K for the fiscal year ended December 31, 2005. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

Source: Business Wire

More News in this Category